ABSTRACT
Objectives To compare the co-administration of an Ayurvedic drug AYUSH 64 as an adjunct to standard of care (SOC) and SOC for efficacy and safety in the management of COVID-19.
Design Multicentre, parallel efficacy, randomized, controlled, open label, assessor blind, exploratory trial with a convenience sample. Patients followed to complete 12 weeks of study duration.
Setting COVID-19 dedicated non-intensive care wards at 1 government hospital, 1 medical college teaching hospital and 1 medical university teaching hospital
Participants 140 consenting, eligible, hospitalized adult patients suffering from mild and moderate symptomatic COVID-19 and confirmed by a diagnostic (SARS-CoV-2) RT-PCR assay on nasal and throat swab were randomized to SOC or SOC plus AYUSH 64. To be withdrawn if disease becomes severe.
Interventions Two tablets of AYUSH 64, 500 mg each, twice daily after meals, and continued till study completion. SOC (symptomatic and supportive) as per national guidelines of India for mild and moderate disease.
Main outcome measures Time period to clinical recovery (CR) from randomization baseline and proportion with CR within 28 days time frame; CR defined in the protocol
Results 140 patients randomized (70 in each arm); 138 patients with CR qualified for analysis. Both groups were matched at baseline. The mean time to CR from randomization was significantly superior in AYUSH 64 group (95% CI -3.03 to 0.59 days); a higher proportion (69.7%) in the first week (p=0.046, Chi-square). No significant differences observed for COVID-19 related blood assays (such as D-Dimer). AYUSH 64 arm showed significant (p<0.05) superior persistent improvement in general health, quality of life, fatigue, anxiety, stress, sleep and other psychosocial metrics. 1 patient on SOC required critical care. 48 adverse events (AE) reported in each group. Barring three SAE (in SOC), AE were mild and none were drug related. 22 participants (8 on AYUSH) were withdrawn. No deaths were reported.
Conclusions AYUSH 64 hastened recovery, reduced hospitalization and improved overall health in mild and moderate COVID-19 when co-administered with SOC under medical supervision. It was safe and well tolerated. Further studies are warranted.
Trial registration The Clinical Trials Registry India Number CTRI/2020/06/025557
Funding CCRAS, Ministry of AYUSH, Government of India
Competing Interest Statement
The authors Kuldeep Chaudhary, Alok Srivastava, Govind Reddy, Manohar Gundeti, BCS Rao, Babita Yadav, Narayanam Srikanth work in Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH (MoA), Government of India (GOI), New Delhi. Ashwinikumar Raut was a consultant for the study. Sanjay Tamoli was involved as a CRO. AYUSH-64 is a proprietary formulation of CCRAS.
Clinical Trial
CTRI/2020/06/025557
Funding Statement
This study was funded by Central Council for Research in Ayurvedic Sciences, Ministry of Ayush, Government of India.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee, Datta Meghe Institute of Medical Sciences, Nagpur, India Institutional Ethics Committee, King George Medical University, Lucknow, India Institutional Ethics Committee, R R A Podar Central Ayurveda Research Institute for Cancer, Mumbai, India
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Statement: This study was funded by Central Council for Research in Ayurvedic Sciences, Ministry of Ayush, Government of India.
Competing interests: None of the authors have any financial conflict of interest regarding this study. The authors Kuldeep Chuadhary, Alok Srivastava, Govind Reddy, Manohar Gundeti, BCS Rao, Babita Yadav, Narayanam Srikanth work in Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH (MoA), Government of India (GOI), New Delhi. Dr Ashwinikumar Raut was a consultant for the study. Dr Sanjay Tamoli was involved as a CRO. AYUSH-64 is a proprietary formulation of CCRAS.
Contact Address: Arvind Chopra, MD, Director and Chief Rheumatologist, Centre for Rheumatic Diseases, Pune, India 411001, Telephone: +91 20 26345624, (M) 9822039297, Email: crdp5624{at}gmail.com
Data Availability
Not applicable
http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=43812&EncHid=&userName=025557
